WideCells Group PLC GM Results (5098H)
16 November 2018 - 12:03AM
UK Regulatory
TIDMWDC
RNS Number : 5098H
WideCells Group PLC
15 November 2018
15 November 2018
WideCells Group PLC ('WideCells Group' or 'the Group')
Results of General Meeting
WideCells Group PLC, the healthcare services company focused on
providing stem cell services and ground-breaking insurance for stem
cell treatment, is pleased to announce that all resolutions put to
the Group's General Meeting held earlier today were duly passed on
a show of hands.
The company had received proxy votes lodged in advance of the
meeting showing over 98% of votes cast in favour of the
resolutions.
**ENDS**
For further information, please visit the Company's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919 033
171
Shard Capital Partners Broker - Damon Heath & Erik Tel: +44 (0) 20 7186
LLP Woolgar 9950
---------------------------- ---------------------
St Brides Partners PR - Priit Piip & Isabel de Tel: +44 (0) 20 7236
Limited Salis 1177
---------------------------- ---------------------
Notes to Editors
WideCells Group PLC
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments both accessible and
affordable. This is delivered through three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process.
-- WideCells: The Institute of Stem Cell Technology has been
established and is based in the University of Manchester Innovation
Centre to focus on stem cell research and regenerative medicine.
WideCells also has international cryogenics divisions specialising
in stem cell storage.
-- Wideacademy: developing an education and training division to
promote awareness of the benefits of stem cell storage across the
global general practice community.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families, because it is
simple, safe and painless to collect, relative to other sources of
stem cells such as bone marrow - WideCells will focus on promoting
the collection and storage of cord blood.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells.
-- 82 illnesses can currently be treated using stem cell procedures.
-- Despite initial collection and storage often costing no more
than a few GBPthousands, actual treatment can cost in the
GBPhundreds of thousands - before the development of an insurance
product such as CellPlan, the treatment remained largely available
only to Higher Net Worth individuals.
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014
(MAR).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMBABTTMBABBAP
(END) Dow Jones Newswires
November 15, 2018 08:03 ET (13:03 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Apr 2024 to May 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From May 2023 to May 2024